Jakub Czechowicz

Mr. Jakub Czechowicz


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Polymers
Verified
Journal Article
Open access
PDF file
MZMagdalena Zaręba
Magdalena Zaręba
MTMagdalena Twardowska
Magdalena Twardowska
PBPaweł Błoniarz
Paweł Błoniarz
JLJaromir B. Lechowicz
Jaromir B. Lechowicz
JCJakub Czechowicz
Jakub Czechowicz
ŁUŁukasz Uram
Łukasz Uram
Systemic anticancer therapy causes a number of side effects; therefore, local drug release devices may play an important role in this area. In this study, we developed polyurethane-dendrimer foams containing different amounts of third-generation poly (amidoamine) dendrimers (PAMAM G3) to evaluate their ability to encapsulate and release the model anticancer drug doxorubicin (DOX), as well as their biocompatibility and effectiveness against normal and cancer cells in vitro. PU–PAMAM foams containing 10–50 wt% PAMAM G3 were prepared using glycerin-based polyether polyol and castor oil as co-components. Structural and rheological analyses revealed that foams containing up to 20 wt% PAMAM G3 exhibited a well-developed porous structure, while higher dendrimer loadings (≥30 wt%) led to irregular cell shapes, pore coalescence, and thinning of cell walls, and indicated a gradual loss of structural integrity. Rheological creep–recovery measurements confirmed the structural findings: moderate PAMAM G3 incorporation (≤20 wt%) increased both the instantaneous and delayed elastic modulus (E1 ≈ 130–140 kPa; E2 ≈ 80 kPa) and enhanced elastic recovery, reflecting improved cross-link density and foam stability. Higher dendrimer contents (30–50 wt%) caused a decline in these parameters and higher viscoelastic compliance, indicating a softer, less stable structure. The DOX loading capacity and encapsulation efficiency increased with PAMAM G3 content, reaching maximum values of 35% and 51% for 30–40 wt% PAMAM G3, respectively. However, the most sustained DOX release profiles were observed for matrices containing 20 wt% PAMAM G3. Analysis of cumulative release and kinetic modeling revealed a transition from diffusion-controlled release at low PAMAM contents to burst-dominated release at higher dendrimer loadings. Importantly, matrices containing 10–20 wt% PAMAM G3 also indicated selective anticancer action against squamous cell carcinoma (SCC-15) compared to non-cancerous human keratinocytes (HaCaT). Moreover, the DOX they released effectively destroyed cancer cells. Overall, PU–PAMAM foams containing 10–20 wt% PAMAM G3 provide the most balanced combination of structural stability, controlled drug release, and cytocompatibility. These materials therefore represent a promising platform as passive carriers in drug delivery systems (DDSs), such as local implants, anticancer patches, or bioactive wound dressings.

24 October 2026 in Materials
Verified
Journal Article
Open access
PDF file
MZMagdalena Zaręba
Magdalena Zaręba
MTMagdalena Twardowska
Magdalena Twardowska
ECElżbieta Chmiel-Szukiewicz
Elżbieta Chmiel-Szukiewicz
JCJakub Czechowicz
Jakub Czechowicz
DŁDawid Łysik
Dawid Łysik
ŁUŁukasz Uram
Łukasz Uram
There is growing interest in local drug delivery systems that release their payload in a controlled manner directly at the implantation site. Such systems are particularly valuable in solid tumors, chronic wounds and infections, where systemic administration is constrained by poor tissue penetration and dose-limiting side effects. In this study, hydroxylated poly(amidoamine) (PAMAM) G3 dendrimers were incorporated into polyurethane foams (PU) as multifunctional polyol components to obtain hybrid porous matrices. Surface polyhydroxylation of amine-terminated PAMAM G3 via glycidol ring-opening introduced hydroxyl functionalities that enabled integration of the modified dendrimer into the PU network. Morphological analysis by scanning electron microscopy (SEM) and micro-computed tomography (µCT) confirmed a well-defined cellular architecture without macroscopic defects upon dendrimer incorporation. The modified material exhibited reduced apparent density and increased water absorption compared with the reference PU foam. Rheological creep–recovery analysis demonstrated enhanced delayed elasticity and reduced permanent deformation in the dendrimer-modified matrix, reflecting improved viscoelastic recovery. Mass balance analysis showed higher encapsulation efficiency for the dendrimer-modified foam (34.9%) than for the reference material (29.7%). Despite this higher loading, the cumulative release of doxorubicin (DOX) over 100 h in phosphate-buffered saline (PBS) (pH 7.4, 37 °C) was lower for the modified system (7.0%) than for the reference matrix (15.8%), and the initial burst release after 30 min was six-fold lower, indicating enhanced drug retention and the potential for prolonged release. Biological studies showed that the matrices were non-toxic and highly biocompatible towards human SCC-15 and HaCaT cells in vitro and in the Caenorhabditis elegans model in vivo, whereas DOX released from the matrices effectively killed cancer cells at extract concentrations as low as 3%. These results show that hydroxylated PAMAM G3 acts as a structural modifier of PU foams capable of modulating drug retention and release, and therefore use of dendrimeric matrix as a drug carrier in local therapy is worth considering.